Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Direxion Daily S&P 500 Bear 3X Shares ETF
SPXS
5
ProShares UltraPro Short S&P500 ETF
SPXU
US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 0.8800
- +0.0782+9.75%
Close May 2 16:00 ET
- 0.8799
- -0.0001-0.01%
Post 20:01 ET
81.84MMarket Cap-0.53P/E (TTM)
0.9124High0.7932Low1.02MVolume0.8000Open0.8018Pre Close880.77KTurnover1.22%Turnover RatioLossP/E (Static)93.00MShares3.930052wk High0.32P/B73.87MFloat Cap0.660052wk Low--Dividend TTM83.94MShs Float32.6450Historical High--Div YieldTTM14.87%Amplitude0.6600Historical Low0.8600Avg Price1Lot Size
Market Insights
Discussing
BRK cash at new high: What to expect from Buffett’s meeting?
🎙️Discussion 1. Buffett said he won't sell Japanese stocks for the next ten years. What's your take? 2. In the face of market changes, do y
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
Caribou Biosciences Stock Forum
Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs
Thursday, 24th April at 4:15 pm
-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 --
-- Two robust clinical datasets from CB-010 and CB-011 now expected to be disclosed in H2 2025 --
-- CB-010 ANTLER 2L LBCL Phase 1 dataset expected to include at least six mo...
Thats gonna be so bad for all shareholders…
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Sunday, 12th January at 7:05 pm
-- CB-010 GALLOP Phase 1 trial initiated in lupus --
-- CB-012 AMpLify Phase 1 trial in r/r AML completes dose level 3 with no DLTs; enrolling patients at dose level 4 --
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 --
-- Sri Ryali appointed chief fi...
$Gossamer Bio (GOSS.US)$
$Archer Aviation (ACHR.US)$
Gonna add a position for each again.
Caribou Biosciences Announces the FDA Has Granted Fast Track Designations to CB-010 in Refractory Sle and to CB-012 in Relapsed or Refractory Aml
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
No comment yet